Molecular characterization of human skin response to diphencyprone at peak and resolution phases: therapeutic insights. - Test2 - elhamkhani - TriplyDB

Molecular characterization of human skin response to diphencyprone at peak and resolution phases: therapeutic insights.

Molecular characterization of human skin response to diphencyprone at peak and resolution phases: therapeutic insights.

http://www.wikidata.org/entity/Q34195289

about

Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells.Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis.Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions.Common clonal origin of central and resident memory T cells following skin immunization Unique microRNAs appear at different times during the course of a delayed-type hypersensitivity reaction in human skin The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment The gene expression and immunohistochemical time-course of diphenylcyclopropenone-induced contact allergy in healthy humans following repeated epicutaneous challenges.TH9 cells in skin disorders.Epidermal cornification is preceded by the expression of a keratinocyte-specific set of pyroptosis-related genes.Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study.Biomarkers of alopecia areata disease activity and response to corticosteroid treatment.Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases of the skin; the 5-year Norwich experience.Debunking the Myth of Exercise-Induced Immune Suppression: Redefining the Impact of Exercise on Immunological Health Across the Lifespan.

P2860

Q34408962-295FCED0-ACD0-4752-AE71-88DC761F8DBF Q35522947-327FA7BF-6542-43E5-A9A4-0E578EFD21BA Q35861578-E7807C67-67D6-4C28-BA70-545B8A7A91BF Q36246184-42A38EC9-A192-4D73-AAD8-8A401AAE3EE3 Q36431037-4C557E78-12F7-417E-91B0-629412068C25 Q36984717-F9BF4EFD-6BB1-4519-A4A7-3ACD874FE0AE Q37052951-3FE8445D-B487-4A0F-92BC-D45B056F8295 Q38859444-81F2777C-031B-4A6C-B030-A0511E1ACD87 Q38948052-CF516525-4336-41E2-9FFC-30F0ED26C60B Q46242608-FFEA29A2-2611-4F6F-B5EF-8F6C4DF0457A Q50016369-57B61EAA-B126-4B7A-86BC-2C16AAFC8FEA Q53246365-EAC98621-0045-44A5-A828-2EDB73B8F745 Q54628831-70973C0B-AD49-453B-BA0C-F431FEF18DD5 Q55130373-6561799D-0B55-4862-97EE-63979A882B44

P2860

Molecular characterization of human skin response to diphencyprone at peak and resolution phases: therapeutic insights.

http://www.wikidata.org/entity/Q34195289

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Molecular characterization of ...... phases: therapeutic insights.

@ast

Molecular characterization of ...... phases: therapeutic insights.

@en

Molecular characterization of ...... phases: therapeutic insights.

@nl

type

label

Molecular characterization of ...... phases: therapeutic insights.

@ast

Molecular characterization of ...... phases: therapeutic insights.

@en

Molecular characterization of ...... phases: therapeutic insights.

@nl

prefLabel

Molecular characterization of ...... phases: therapeutic insights.

@ast

Molecular characterization of ...... phases: therapeutic insights.

@en

Molecular characterization of ...... phases: therapeutic insights.

@nl

P1433

Q34195289-2932CCB2-A611-4664-A933-A960CECDEEE1

P1476

Q34195289-BF61835B-2724-4715-8078-77D07FF2D272

P2093

Q34195289-0340A814-99EC-4050-872F-554BD6656F89

Q34195289-92F99A0C-C360-4A76-B3D2-A791D6FB2FAF

Q34195289-9B2E311C-A589-4EA4-ADA9-35E546D6D09D

Q34195289-ACAF4B63-DE13-42C0-B653-C1F50F830871

Q34195289-B2D24431-6487-4687-B4A9-E18A8A7641D9

Q34195289-B98653BD-9A3F-4886-84D9-ABEDDDDEAF62

Q34195289-D46C86D3-0B89-4544-99B3-2CD9BB6AA3E7

Q34195289-F49777FC-445A-4EA8-9D75-5701720B8D95

P2860

Q34195289-05341A91-2196-4ABF-A1B0-2EB874C58162

Q34195289-134A8441-B5A6-40D9-9FEE-46417317C4A1

Q34195289-15BD9569-40D9-4DB6-B996-BB6E71E4EED6

Q34195289-1843184B-8C12-4A3C-A782-E849A1EF9883

Q34195289-1D3B840A-02A4-4B8F-B400-64097194DE36

Q34195289-1DF597A7-BEF6-4500-9C48-1079A4F83FA3

Q34195289-228E519A-BBCC-4619-A141-828140EE8819

Q34195289-238120B7-386B-4CE5-9B78-37AFA52A5C74

Q34195289-269D0730-266D-4586-B81F-188B92A1FBBC

Q34195289-2A276424-58BE-4667-B6B3-09AC46D9690F

P2888

Q34195289-547C3D29-7B9F-40D1-B80F-4EF1C0AB6740

P304

Q34195289-35E517F0-2DBD-47E1-B249-49DBEE40E72F

P31

Q34195289-C489E0A5-1B80-4C40-B938-A2C140D99FBC

P356

Q34195289-0723D59C-48EA-408C-8A3F-C6F6470C59C4

P407

Q34195289-8FFFE404-B97B-434D-A38A-A422B3752313

P433

Q34195289-95DA47AE-5F7C-4D32-B312-1E057A279D07

P478

Q34195289-AFAED797-4A5C-4177-BF5C-323A17F2436A

P50

Q34195289-E8D4BFDA-2F83-4D96-B731-D7EE67675C2D

P577

Q34195289-D99B9B40-D0DD-4155-B35E-2F3AF54DA4AD

P5875

Q34195289-CF3048C1-E985-45CB-96E5-9392F0117254

P6179

Q34195289-03432F43-29D7-486A-B45E-B7674BBB3F25

P698

Q34195289-684CF9CC-5624-4696-8D99-82EE6D0F5F36

P921

Q34195289-B1D8AA56-2300-46DF-9A79-2EE53009128F

P932

Q34195289-1013BC86-22CB-47BD-A966-53B16EED6DC2

P356

P1433

Journal of Investigative Dermatology

P1476

Molecular characterization of ...... phases: therapeutic insights.

@en

P2093

Hiroshi Mitsui

http://www.w3.org/2001/XMLSchema#string

Inna Cueto

http://www.w3.org/2001/XMLSchema#string

James G Krueger

http://www.w3.org/2001/XMLSchema#string

Judilyn Fuentes-Duculan

http://www.w3.org/2001/XMLSchema#string

Mary Sullivan-Whalen

http://www.w3.org/2001/XMLSchema#string

Mayte Suárez-Fariñas

http://www.w3.org/2001/XMLSchema#string

Nicholas Gulati

http://www.w3.org/2001/XMLSchema#string

Patricia Gilleaudeau

http://www.w3.org/2001/XMLSchema#string

P2860

Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells

Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator

Foxp3+ regulatory T cells maintain immune homeostasis in the skin

The use of diphenylcyclopropenone in the treatment of recalcitrant warts.

Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression.

Aire-dependent production of XCL1 mediates medullary accumulation of thymic dendritic cells and contributes to regulatory T cell development.

L-arginine metabolism in myeloid cells controls T-lymphocyte functions.

Alopecia areata: treatment of today and tomorrow.

Transcriptional profiling of innate and adaptive human immune responses to mycobacteria in the tuberculin skin test.

Skin inflammation arising from cutaneous regulatory T cell deficiency leads to impaired viral immune responses.

P2888

P304

2531-2540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/JID.2014.196

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

134

http://www.w3.org/2001/XMLSchema#string

P50

Joel Correa Da Rosa

P577

2014-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261769762

http://www.w3.org/2001/XMLSchema#string

P6179

1037444464

http://www.w3.org/2001/XMLSchema#string

P698

24751728

http://www.w3.org/2001/XMLSchema#string

P921

P932

4165712

http://www.w3.org/2001/XMLSchema#string